Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Journal article
Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Journal article
Hanekamp D. et al, (2020), Br J Haematol, 190, 891 - 900
Mechanisms of Response and Resistance to AML Therapies.
Journal article
Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.
Journal article
Roos-Weil D. et al, (2020), Blood, 136, 585 - 595
A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome.
Journal article
Bache I. et al, (2020), Blood Cancer J, 10
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Journal article
Labuhn M. et al, (2019), Cancer Cell, 36
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Journal article
Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.
Journal article
Roos-Weil D. et al, (2019), Cancer Discov, 9, 796 - 811
Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood
Conference paper
Hanssen L. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 106 - 106
Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome
Conference paper
Labuhn M. et al, (2018), BLOOD, 132
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Journal article
Quek L. et al, (2018), Nat Med, 24, 1167 - 1177
Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
Conference paper
Quek L. et al, (2017), BLOOD, 130
Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS
Conference paper
Roberts I. et al, (2017), BLOOD, 130
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
Journal article
Craddock CF. et al, (2017), Clin Cancer Res, 23, 6430 - 6440
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY
Conference paper
Craddock C. et al, (2017), HAEMATOLOGICA, 102, 323 - 323
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.
Journal article
Quek L. et al, (2016), Blood Adv, 1, 193 - 204
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Journal article
Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535
NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE
Conference paper
Quek L. et al, (2016), HAEMATOLOGICA, 101, 213 - 213